| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 4.72 | 6.72 | 6.93 | 9.26 | 11.36 | 30.93 | 28.97 | 18.74 | 0.17 | — |
| Quick Ratio | 4.72 | 6.72 | 6.93 | 9.26 | 11.36 | 30.93 | 28.97 | 18.74 | 0.17 | — |
| Debt / Equity | 0.30 | 0.40 | 0.27 | 0.18 | 0.11 | 0.09 | — | — | — | — |
| ROE | -146.12% | -117.25% | -98.01% | -76.54% | -40.25% | -15.46% | -13.71% | -47.73% | 40.64% | — |
| ROA | -65.42% | -52.51% | -54.34% | -50.08% | -29.53% | -12.47% | -13.20% | -44.95% | -861.16% | — |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Book Value / Share | 2.96 | 2.86 | 5.07 | 8.35 | 12.81 | 18.82 | — | — | — | — |
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for retinal diseases. The company specializes in next-generation therapies targeting chronic, high-prevalence ophthalmic conditions that lead to vision loss, including wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, uveitis, and macular edema secondary to inflammation. Its proprietary Antibody Biopolymer Conjugate Drug platform enables multi-modal treatments through bio-inspired antibody biopolymer conjugates. Key pipeline candidates include tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer in Phase 3 studies for retinal vascular diseases; KSI-501, a bispecific anti-IL-6 and VEGF-trap for inflammatory retinal conditions; and KSI-101, targeting IL-6 and VEGF for patients with retinal fluid and inflammation. Kodiak Sciences Inc. operates as a retina-focused biotechnology firm advancing late-stage programs to address unmet needs in ophthalmology. Founded in 2009 and headquartered in Palo Alto, California, it remains committed to developing innovative biologic medicines for complex ocular diseases.